新型调脂抗动脉粥样硬化药物进展概况  

Review of novel lipid-regulating and antiatherosclerosis drugs

作　　者：杜文婷[1] 顾耘[1] Du Wenting;Gu Yun(Department of Geriatrics,Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine,Shanghai,200032,China)

机构地区：[1]上海中医药大学附属龙华医院老年科

出　　处：《当代医学》2020年第1期192-194,共3页Contemporary Medicine

基　　金：上海青年医师培养资助计划（第五批）;上海市科学技术委员会项目（18ZR1440100）;国家中医药管理局全国名老中医药专家传承工作室建设项目“林水淼全国名老中医传承工作室”

摘　　要：动脉粥样硬化是众多心脑血管疾病发生的病理基础,严重危害人类健康。长期血脂水平失调,是动脉粥样硬化发生的重要危险因素。近年来,随着人民生活膳食结构、生活习惯的改变,血脂紊乱在我国的发病率显著升高。因此,有效调节血脂水平,预防动脉粥样硬化形成,降低心脑血管事件发生率,具有重要临床意义。本文就近年来新型调脂、抗动脉粥样硬化药物及其相关研究进行综述。Atherosclerosis is the pathological basis of many cardiovascular and cerebrovascular diseases,which is seriously harmful to human healthy.Long-term imbalance of blood lipid level is an important risk factor for atherosclerosis.In recent years,with the change of people’s dietary structure and living style,the incidence of dyslipidemia has significantly increased in China.Therefore,it is of great clinical significance to effectively regulate the level of blood lipid,prevent atherosclerosis and reduce the incidence of cardiovascular and cerebrovascular events.In this paper,the recent development of new lipid-regulating and anti-atherosclerosis drugs and their related studies are reviewed.

关 键 词：调脂 动脉粥样硬化 现代医学 进展 

分 类 号：R54[医药卫生—心血管疾病]